Generated by AI
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies. Its products are used by biopharmaceutical companies and contract development and manufacturing organizations to improve efficiency, control, and consistency in production processes. The company offers consumables and instruments such as Protein A ligands, chromatography columns, filtration systems, and analytical tools designed for biologics processing. Headquartered in Waltham, Massachusetts, Repligen Corporation serves customers across North America, Europe, the Asia Pacific, and other international markets, making it an important supplier within the bioprocessing and life sciences tools sector.
WebsiteBuilding 1
Waltham, MA, 02453
United States
The latest articles about RGEN.
Repligen has had a mixed run, with the share price at US$162.78 after several years of uneven returns. This puts fresh focus on whether the current market value lines up with the cash the business can generate over time. For anyone considering the stock today, the live question is how that cash flow story stacks up against the recent performance profile. Over the past 5 years, Repligen shares have fallen 40.6%, which puts longer term cash flow prospects under the microscope despite shorter...
Summary of Oct 27's posts. Generated by AI.
No summary yet.
Summary of Apr 27's posts. Generated by AI.
Summary of Jul 28's posts. Generated by AI.
Investors talking about RGEN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.